The prognostic value of cell‐free DNA dynamics during chemoradiotherapy in squamous cell carcinomas of the anus
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70156 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Anne Vittrup Jakobsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Chemoradiotherapy, Cell-Free Nucleic Acids, Biomarkers, Tumor, Anus Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Region Midtjylland, Nordic Cancer Union, Inger Holms Minnefond.
Abstract (Originalsprache)
Reliable biomarkers for assessing prognosis and monitoring response to chemoradiotherapy (CRT) are lacking in squamous cell carcinomas of the anus (SCCA). Liquid biopsies measuring cell‐free DNA (cfDNA) by direct fluorescent assay (DFA) provide a simple, non‐invasive approach. This study aims to investigate the prognostic value of cfDNA dynamics during CRT. Blood samples and clinical data were prospectively collected from SCCA patients undergoing CRT. Serum cfDNA levels (ng/μL) were quantified using DFA at baseline, mid‐therapy, and end of treatment (EOT). Baseline levels were analyzed in relation to patient characteristics using Mann–Whitney U test and over time with Wilcoxon signed‐rank test. Survival was evaluated using Kaplan–Meier curves and log‐rank test. In total, 126 patients were included, with cfDNA measurements at baseline ( n = 126), mid‐therapy ( n = 103) and EOT ( n = 108). Median cfDNA levels were 0.78 ng/μL 95% CI (0.72–0.85), 0.62 ng/μL 95% CI (0.56–0.72), and 0.66 ng/μL 95% CI (0.58–0.74), respectively. Baseline cfDNA levels were higher in patients with high‐risk disease (T3‐T4, N+ or M+) and performance status 1–2 ( p < .05), but this did not appear to affect outcomes. cfDNA levels declined from baseline to mid‐therapy and EOT ( p < .001). A lower percentage decline was observed in non‐responders (−9% 95% CI (−24; 33) and −37% 95% CI (−44; −29), p = .002) and treatment failures (−18% 95% CI (−36; 9) and −36% 95% CI (−44; −28), p = .02). Failure to eliminate below the baseline 75th percentile was associated with inferior disease‐free survival (HR = 4.23 95% CI (1.50–11.93), p = .003). In conclusion, cfDNA quantification by DFA is feasible in SCCA. Low cfDNA elimination during CRT was associated with poorer outcomes, highlighting the clinical potential of cfDNA dynamics as a prognostic biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- The Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Anne Vittrup Jakobsen
Förderung
- Region Midtjylland
- Nordic Cancer Union
- Inger Holms Minnefond
- Aase og Ejnar Danielsens Fond
- Einar Willumsen Foundation
- Dansk Kræftforsknings Fond
- Danish Cancer Society Research Center
- DCCC ctDNA Research Center
Zitieren
APA
Jakobsen, A. V., Kronborg, C., Ramlov, A., Hvid, C. A., & Spindler, K. G. (2026). The prognostic value of cell‐free DNA dynamics during chemoradiotherapy in squamous cell carcinomas of the anus. International Journal of Cancer. https://doi.org/10.1002/ijc.70156
Vancouver
Jakobsen AV, Kronborg C, Ramlov A, Hvid CA, Spindler KG. The prognostic value of cell‐free DNA dynamics during chemoradiotherapy in squamous cell carcinomas of the anus. International Journal of Cancer. 2026. doi:10.1002/ijc.70156
BibTeX
@article{Jakobsen2026,
author = {Jakobsen, Anne Vittrup and Kronborg, Camilla and Ramlov, Anne and Hvid, Christian Andreas and Spindler, Karen-Lise Garm},
title = {The prognostic value of cell‐free DNA dynamics during chemoradiotherapy in squamous cell carcinomas of the anus},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70156}
}
EUVIMED